China Resources Double-Crane Pharmaceutical Co.,Ltd.

Equities

600062

CNE000000Q94

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
20.25 CNY +0.25% Intraday chart for China Resources Double-Crane Pharmaceutical Co.,Ltd. -4.80% +8.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CR Double-Crane Pharma Unit Receives Approval for Epilepsy Drug MT
CR Double-Crane Pharma's 2023 Profit Jumps 13%, Operating Income Climbs 6% MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CR Double-crane Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion. CI
CR Double-Crane Pharma Gets Nod for Apixaban Tablets; Unit's Clozapine Orally Disintegrating Tablets Gets Greenlight for Proposed Amendments MT
CR Double-Crane Pharma's Unit Gets Nod to Market Lithium Carbonate Drug Ingredient MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Raise Strength of Viagra Drug MT
China Includes CR Double-Crane Pharmaceutical's Two Drugs in List of Insurance-Backed Drugs MT
CR Double-Crane Pharma Unit Gets Nod to Amend Sodium Lactate Ringer Injection's Details MT
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from Shanghai Stock Exchange 180 Value Index CI
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from SSE 180 Index CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd. CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
CR Double-Crane Pharma to Buy 90% Stake in Local Peer For 260 Million Yuan MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
CR Double-Crane Pharma Gets Regulatory Nod to Amend Instructions for Lansoprazole for Injection MT
CR Double-Crane Pharma Units Get Regulatory Approvals in China MT
CR Double-Crane Pharma Unit Secures Registration Approval for Gout Drug in China MT
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) added to Shanghai Stock Exchange 180 Value Index CI
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) added to SSE 180 Index CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
CR Double-Crane Pharma Unit's Brain Drug Passes Regulator's Evaluation MT
CR Double-Crane Pharma Applies to Have Three Medicines Added to China’s Drug Procurement Scheme MT
Chart China Resources Double-Crane Pharmaceutical Co.,Ltd.
More charts
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.25 CNY
Average target price
24.91 CNY
Spread / Average Target
+23.03%
Consensus

Annual profits - Rate of surprise